Wedu Medical, Hengdian Group’s medical devices company, has recently received the strictest government approval to make the popular anti-aging treatment "Sculptra," commonly called "Baby Face Needle" in China for its youthening effects. 

This approval, the Class III Medical Device Registration Certificate, comes after a long period of rigorous research and clinical trials that fully assessed Wedu’s ability to ensure the safety, effectiveness and stability of “Sculptra.”

"Sculptra" is a popular injectable known for its ability to stimulate the skin’s own collagen regeneration, unlike traditional fillers which immediately plump the skin. "Sculptra" is said to be able to more fundamentally improve skin texture and facial rejuvenation for multiple years. 

Under Chinese national regulations, “Sculptra” is classified the highest-risk category of medical devices as an injectable filler. This makes Wedu’s government approval a key measure of safety, effectiveness, and stability, and is extremely important in ensuring technical strength and compliance for medical aesthetics companies.

The Class III Medical Device Registration Certificate for Wedu’s "Sculptra" was granted by the National Medical Products Administraton (NMPA). It allows Wedu to produce and sell Poly-L-lactic acid microsphere filler for injection," the core component of "Sculptra."

Since 2019, Wedu's "Sculptra" has undergone a comprehensive process involving more than 6 years of research, clinical trials and approval to ensure market readiness. Its formula uses an active ingredient content of 75%, which brings multiple improvements in safety and effectiveness. 

“Sculptra” is now Wedu’s first approved injectable Class III medical device. It marks the company's official entry into the regenerative medical aesthetics consumer market and is a key upgrade to its product lineup.

Wedu Medical started as Hengdian Group’s minimally invasive surgical device manufacturer. It has now entered the plastic surgery and aesthetics field following decades of deep cultivation, with various facial procedures including “Weilamei” and “Feilingxian.”

Going forward, Wedu will focus on the regenerative medical aesthetics track and continuously prioritize its product safety, quality and tech innovation. It will continue to invest heavily in R&D to strategically support the growth of Hengdian Group.